Integra LifeSciences/$IART
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Integra LifeSciences
Integra Lifesciences Holdings Corp is a New Jersey-based medical equipment company focused on developing products for regenerative therapy, extremity orthopedics, and neurosurgical applications. The firm is organized into two primary segments: Codman specialty surgical and tissue technologies. Codman Specialty Surgical generates maximum revenue from its segmental operations. Integra serves Europe, Asia Pacific, and the rest of the world whilst it derives key revenue from domestic sales.
Ticker
$IART
Sector
Primary listing
Employees
4,396
Headquarters
Website
IART Metrics
BasicAdvanced
$1.2B
-
-$6.54
1.17
-
Price and volume
Market cap
$1.2B
Beta
1.17
52-week high
$27.13
52-week low
$11.06
Average daily volume
1.5M
Financial strength
Current ratio
1.229
Quick ratio
0.579
Long term debt to equity
133.537
Total debt to equity
194.07
Interest coverage (TTM)
1.95%
Profitability
EBITDA (TTM)
305.803
Gross margin (TTM)
57.52%
Net profit margin (TTM)
-30.87%
Operating margin (TTM)
9.41%
Effective tax rate (TTM)
10.41%
Revenue per employee (TTM)
$370,000
Management effectiveness
Return on assets (TTM)
2.43%
Return on equity (TTM)
-38.92%
Valuation
Price to revenue (TTM)
0.73
Price to book
1.16
Price to tangible book (TTM)
-1.57
Price to free cash flow (TTM)
-24.983
Free cash flow yield (TTM)
-4.00%
Free cash flow per share (TTM)
-0.619
Growth
Revenue change (TTM)
3.53%
Earnings per share change (TTM)
-2,292.09%
3-year revenue growth (CAGR)
1.15%
10-year revenue growth (CAGR)
6.96%
3-year earnings per share growth (CAGR)
49.18%
10-year earnings per share growth (CAGR)
26.86%
What the Analysts think about IART
Analyst ratings (Buy, Hold, Sell) for Integra LifeSciences stock.
Bulls say / Bears say
Major brokers Jefferies and Oppenheimer have lowered their price targets on IART to $67 (from $73) and $60 (from $70) respectively, pointing to concerns about the company’s slowing organic growth and persistent operational challenges. (Reuters)
Piper Sandler and UBS have also reduced their price targets on IART to $53 and $55 respectively, citing margin pressures due to higher tariffs and increased costs from quality remediation efforts. (Reuters)
The average analyst price target for IART has dropped by about 20% in the past few months—from nearly $74 down to around $59—highlighting widespread skepticism about the stock’s prospects for a near-term recovery. (Reuters)
Data summarised monthly by Lightyear AI. Last updated on 30 Aug 2025.
IART Financial Performance
Revenues and expenses
IART Earnings Performance
Company profitability
IART News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Integra LifeSciences stock?
Integra LifeSciences (IART) has a market cap of $1.2B as of September 13, 2025.
What is the P/E ratio for Integra LifeSciences stock?
The price to earnings (P/E) ratio for Integra LifeSciences (IART) stock is 0 as of September 13, 2025.
Does Integra LifeSciences stock pay dividends?
No, Integra LifeSciences (IART) stock does not pay dividends to its shareholders as of September 13, 2025.
When is the next Integra LifeSciences dividend payment date?
Integra LifeSciences (IART) stock does not pay dividends to its shareholders.
What is the beta indicator for Integra LifeSciences?
Integra LifeSciences (IART) has a beta rating of 1.17. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.